Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism
Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ...
Gespeichert in:
Veröffentlicht in: | Toxicological sciences 2011-06, Vol.121 (2), p.234-244 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 244 |
---|---|
container_issue | 2 |
container_start_page | 234 |
container_title | Toxicological sciences |
container_volume | 121 |
creator | Szabo, David Taylor Diliberto, Janet J Hakk, Heldur Huwe, Janice K Birnbaum, Linda S |
description | Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10, 10, and 80% of the mixture, respectively. Despite its small contribution to HBCD global production and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including breast milk and blood in North America, European Union, and Asia. No mammalian or human data are currently available regarding the toxicokinetics of α-HBCD. This study was conducted in an effort to fully characterize the absorption, distribution, metabolism, and elimination of α-HBCD following a single and repeated exposure with respect to dose, time, and route of administration in female C57BL/6 mice. Results indicate that ∼90% of the administered dose (3 mg/kg) was absorbed after oral exposure. Disposition was (1) dictated by lipophilicity, as adipose, liver, muscle, and skin were major depots and (2) was dose dependent with nonlinear accumulation at higher doses. Elimination, both whole-body and from individual tissues, was biphasic. α-HBCD-derived radioactivity was excreted in the feces as parent and metabolites, whereas urine only contained metabolites. Presence of polar metabolites in the blood and urine were a major factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial half-lives were ∼1-3 days and much longer terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD bioaccumulation. A 10-day repeated study supports α-HBCD bioaccumulation potential. Stereoisomerization previously observed after exposure to γ-HBCD was not seen after exposure of α-HBCD. The toxicokinetic behavior reported here has important implications for the extrapolation of toxicological studies of the commercial HBCD mixture to the assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people. |
doi_str_mv | 10.1093/toxsci/kfr059 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_toxsci_kfr059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21441408</sourcerecordid><originalsourceid>FETCH-LOGICAL-c331t-2a2bab04dd6c9c282820b362a61c4a5dedd9ba16e39b555365138fce7f2a7cc83</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0EolA4ckV-gIbacZLG3FDFn1SJSzlHa3tNQ5M4sl0pvfPgpGpBe9id0ewcPkLuOHvgTIp5dEPQ9XxrPcvlGbkazSJhMpXnp7tgJZuQ6xC-GeO8YPKSTFKeZTxj5RX5Wbuh1m5bdxhrHaizNG6Q2gZapB4jeANdpBscQHnXOr3XjTPOoIYOKTT9Bh4pWos6Hn6NCzijsW7r7mtGvdvFUXrsESIaikPvws6PFnSGtmO7ck0d2htyYaEJeHvaU_L58rxeviWrj9f35dMq0ULwmKSQKlAsM6bQUqflOEyJIoWC6wxyg8ZIBbxAIVWe56LIuSitxoVNYaF1KaYkOfZq70LwaKve1y34fcVZdaBZHWlWR5pj_v6Y73eqRfOf_sMnfgExpHY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Szabo, David Taylor ; Diliberto, Janet J ; Hakk, Heldur ; Huwe, Janice K ; Birnbaum, Linda S</creator><creatorcontrib>Szabo, David Taylor ; Diliberto, Janet J ; Hakk, Heldur ; Huwe, Janice K ; Birnbaum, Linda S</creatorcontrib><description>Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10, 10, and 80% of the mixture, respectively. Despite its small contribution to HBCD global production and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including breast milk and blood in North America, European Union, and Asia. No mammalian or human data are currently available regarding the toxicokinetics of α-HBCD. This study was conducted in an effort to fully characterize the absorption, distribution, metabolism, and elimination of α-HBCD following a single and repeated exposure with respect to dose, time, and route of administration in female C57BL/6 mice. Results indicate that ∼90% of the administered dose (3 mg/kg) was absorbed after oral exposure. Disposition was (1) dictated by lipophilicity, as adipose, liver, muscle, and skin were major depots and (2) was dose dependent with nonlinear accumulation at higher doses. Elimination, both whole-body and from individual tissues, was biphasic. α-HBCD-derived radioactivity was excreted in the feces as parent and metabolites, whereas urine only contained metabolites. Presence of polar metabolites in the blood and urine were a major factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial half-lives were ∼1-3 days and much longer terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD bioaccumulation. A 10-day repeated study supports α-HBCD bioaccumulation potential. Stereoisomerization previously observed after exposure to γ-HBCD was not seen after exposure of α-HBCD. The toxicokinetic behavior reported here has important implications for the extrapolation of toxicological studies of the commercial HBCD mixture to the assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people.</description><identifier>ISSN: 1096-6080</identifier><identifier>EISSN: 1096-0929</identifier><identifier>DOI: 10.1093/toxsci/kfr059</identifier><identifier>PMID: 21441408</identifier><language>eng</language><publisher>United States</publisher><subject>Administration, Oral ; Animals ; Biotransformation ; Chromatography, Liquid ; Chromatography, Thin Layer ; Dose-Response Relationship, Drug ; Endocrine Disruptors - pharmacokinetics ; Female ; Flame Retardants - pharmacokinetics ; Hydrocarbons, Brominated - pharmacokinetics ; Injections, Intravenous ; Mass Spectrometry ; Mice ; Mice, Inbred C57BL ; Nonlinear Dynamics ; Risk Assessment ; Time Factors ; Tissue Distribution</subject><ispartof>Toxicological sciences, 2011-06, Vol.121 (2), p.234-244</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c331t-2a2bab04dd6c9c282820b362a61c4a5dedd9ba16e39b555365138fce7f2a7cc83</citedby><cites>FETCH-LOGICAL-c331t-2a2bab04dd6c9c282820b362a61c4a5dedd9ba16e39b555365138fce7f2a7cc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21441408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szabo, David Taylor</creatorcontrib><creatorcontrib>Diliberto, Janet J</creatorcontrib><creatorcontrib>Hakk, Heldur</creatorcontrib><creatorcontrib>Huwe, Janice K</creatorcontrib><creatorcontrib>Birnbaum, Linda S</creatorcontrib><title>Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism</title><title>Toxicological sciences</title><addtitle>Toxicol Sci</addtitle><description>Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10, 10, and 80% of the mixture, respectively. Despite its small contribution to HBCD global production and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including breast milk and blood in North America, European Union, and Asia. No mammalian or human data are currently available regarding the toxicokinetics of α-HBCD. This study was conducted in an effort to fully characterize the absorption, distribution, metabolism, and elimination of α-HBCD following a single and repeated exposure with respect to dose, time, and route of administration in female C57BL/6 mice. Results indicate that ∼90% of the administered dose (3 mg/kg) was absorbed after oral exposure. Disposition was (1) dictated by lipophilicity, as adipose, liver, muscle, and skin were major depots and (2) was dose dependent with nonlinear accumulation at higher doses. Elimination, both whole-body and from individual tissues, was biphasic. α-HBCD-derived radioactivity was excreted in the feces as parent and metabolites, whereas urine only contained metabolites. Presence of polar metabolites in the blood and urine were a major factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial half-lives were ∼1-3 days and much longer terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD bioaccumulation. A 10-day repeated study supports α-HBCD bioaccumulation potential. Stereoisomerization previously observed after exposure to γ-HBCD was not seen after exposure of α-HBCD. The toxicokinetic behavior reported here has important implications for the extrapolation of toxicological studies of the commercial HBCD mixture to the assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Biotransformation</subject><subject>Chromatography, Liquid</subject><subject>Chromatography, Thin Layer</subject><subject>Dose-Response Relationship, Drug</subject><subject>Endocrine Disruptors - pharmacokinetics</subject><subject>Female</subject><subject>Flame Retardants - pharmacokinetics</subject><subject>Hydrocarbons, Brominated - pharmacokinetics</subject><subject>Injections, Intravenous</subject><subject>Mass Spectrometry</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Nonlinear Dynamics</subject><subject>Risk Assessment</subject><subject>Time Factors</subject><subject>Tissue Distribution</subject><issn>1096-6080</issn><issn>1096-0929</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1OwzAQhC0EolA4ckV-gIbacZLG3FDFn1SJSzlHa3tNQ5M4sl0pvfPgpGpBe9id0ewcPkLuOHvgTIp5dEPQ9XxrPcvlGbkazSJhMpXnp7tgJZuQ6xC-GeO8YPKSTFKeZTxj5RX5Wbuh1m5bdxhrHaizNG6Q2gZapB4jeANdpBscQHnXOr3XjTPOoIYOKTT9Bh4pWos6Hn6NCzijsW7r7mtGvdvFUXrsESIaikPvws6PFnSGtmO7ck0d2htyYaEJeHvaU_L58rxeviWrj9f35dMq0ULwmKSQKlAsM6bQUqflOEyJIoWC6wxyg8ZIBbxAIVWe56LIuSitxoVNYaF1KaYkOfZq70LwaKve1y34fcVZdaBZHWlWR5pj_v6Y73eqRfOf_sMnfgExpHY4</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Szabo, David Taylor</creator><creator>Diliberto, Janet J</creator><creator>Hakk, Heldur</creator><creator>Huwe, Janice K</creator><creator>Birnbaum, Linda S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201106</creationdate><title>Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism</title><author>Szabo, David Taylor ; Diliberto, Janet J ; Hakk, Heldur ; Huwe, Janice K ; Birnbaum, Linda S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c331t-2a2bab04dd6c9c282820b362a61c4a5dedd9ba16e39b555365138fce7f2a7cc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Biotransformation</topic><topic>Chromatography, Liquid</topic><topic>Chromatography, Thin Layer</topic><topic>Dose-Response Relationship, Drug</topic><topic>Endocrine Disruptors - pharmacokinetics</topic><topic>Female</topic><topic>Flame Retardants - pharmacokinetics</topic><topic>Hydrocarbons, Brominated - pharmacokinetics</topic><topic>Injections, Intravenous</topic><topic>Mass Spectrometry</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Nonlinear Dynamics</topic><topic>Risk Assessment</topic><topic>Time Factors</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szabo, David Taylor</creatorcontrib><creatorcontrib>Diliberto, Janet J</creatorcontrib><creatorcontrib>Hakk, Heldur</creatorcontrib><creatorcontrib>Huwe, Janice K</creatorcontrib><creatorcontrib>Birnbaum, Linda S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Toxicological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szabo, David Taylor</au><au>Diliberto, Janet J</au><au>Hakk, Heldur</au><au>Huwe, Janice K</au><au>Birnbaum, Linda S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism</atitle><jtitle>Toxicological sciences</jtitle><addtitle>Toxicol Sci</addtitle><date>2011-06</date><risdate>2011</risdate><volume>121</volume><issue>2</issue><spage>234</spage><epage>244</epage><pages>234-244</pages><issn>1096-6080</issn><eissn>1096-0929</eissn><abstract>Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10, 10, and 80% of the mixture, respectively. Despite its small contribution to HBCD global production and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including breast milk and blood in North America, European Union, and Asia. No mammalian or human data are currently available regarding the toxicokinetics of α-HBCD. This study was conducted in an effort to fully characterize the absorption, distribution, metabolism, and elimination of α-HBCD following a single and repeated exposure with respect to dose, time, and route of administration in female C57BL/6 mice. Results indicate that ∼90% of the administered dose (3 mg/kg) was absorbed after oral exposure. Disposition was (1) dictated by lipophilicity, as adipose, liver, muscle, and skin were major depots and (2) was dose dependent with nonlinear accumulation at higher doses. Elimination, both whole-body and from individual tissues, was biphasic. α-HBCD-derived radioactivity was excreted in the feces as parent and metabolites, whereas urine only contained metabolites. Presence of polar metabolites in the blood and urine were a major factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial half-lives were ∼1-3 days and much longer terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD bioaccumulation. A 10-day repeated study supports α-HBCD bioaccumulation potential. Stereoisomerization previously observed after exposure to γ-HBCD was not seen after exposure of α-HBCD. The toxicokinetic behavior reported here has important implications for the extrapolation of toxicological studies of the commercial HBCD mixture to the assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people.</abstract><cop>United States</cop><pmid>21441408</pmid><doi>10.1093/toxsci/kfr059</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1096-6080 |
ispartof | Toxicological sciences, 2011-06, Vol.121 (2), p.234-244 |
issn | 1096-6080 1096-0929 |
language | eng |
recordid | cdi_crossref_primary_10_1093_toxsci_kfr059 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
subjects | Administration, Oral Animals Biotransformation Chromatography, Liquid Chromatography, Thin Layer Dose-Response Relationship, Drug Endocrine Disruptors - pharmacokinetics Female Flame Retardants - pharmacokinetics Hydrocarbons, Brominated - pharmacokinetics Injections, Intravenous Mass Spectrometry Mice Mice, Inbred C57BL Nonlinear Dynamics Risk Assessment Time Factors Tissue Distribution |
title | Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T20%3A03%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Toxicokinetics%20of%20the%20flame%20retardant%20hexabromocyclododecane%20alpha:%20effect%20of%20dose,%20timing,%20route,%20repeated%20exposure,%20and%20metabolism&rft.jtitle=Toxicological%20sciences&rft.au=Szabo,%20David%20Taylor&rft.date=2011-06&rft.volume=121&rft.issue=2&rft.spage=234&rft.epage=244&rft.pages=234-244&rft.issn=1096-6080&rft.eissn=1096-0929&rft_id=info:doi/10.1093/toxsci/kfr059&rft_dat=%3Cpubmed_cross%3E21441408%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21441408&rfr_iscdi=true |